Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 11/20/20 → 8/16/25 |
Funding
- Mirati Therapeutics Incorporated: $242,514.00
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
- Arnold, Susanne (PI)
- Zinner, Ralph (Former PI)